Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
<p>Multiple myeloma is a fatal haematological malignancy, in which the majority of patients either present with or develop a destructive and debilitating osteolytic bone disease. The bone disease is characterised by an increase in osteoclastogenesis and by osteoblast suppression. Current trea...
Үндсэн зохиолч: | Leng, H |
---|---|
Бусад зохиолчид: | Simon, K |
Формат: | Дипломын ажил |
Хэл сонгох: | English |
Хэвлэсэн: |
2019
|
Нөхцлүүд: |
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Interleukin-32 promotes osteoclast differentiation but not osteoclast activation
-н: Mabilleau, G, зэрэг
Хэвлэсэн: (2009) -
Stimulation of osteoclast formation by inflammatory synovial fluid
-н: Adamopoulos, I, зэрэг
Хэвлэсэн: (2006) -
Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand
-н: Mabilleau, G, зэрэг
Хэвлэсэн: (2008) -
Expression of Receptor Activator of Nuclear – Kappa β Ligand in Patients with Metastatic Bone Disease
-н: Magetsari, Rahadyan, зэрэг
Хэвлэсэн: (2022) -
Maintenance therapy in multiple myeloma
-н: Jean-Luc Harousseau
Хэвлэсэн: (2009-08-01)